Trial Stopped for Abelacimab's Able to Reduce Bleeding in AF.

Published Date: 23 Sep 2023

The investigational Factor XI inhibitor abelacimab exhibits "an overwhelming reduction" in major and clinically relevant nonmajor bleeding when compared to rivaroxaban in the phase 2 AZALEA-TIMI 71 trial in patients with AF.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

How access to specialized cancer centers affects glioblastoma outcomes

2.

Cancer Patients Who Completed Medication Survey Received More Help From Pharmacists

3.

Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.

4.

U.S. Nurse Found Dead; Harvey Weinstein's Cancer; Creepy Source of Ear Pain

5.

Beyond What Is Visible in Myelofibrosis?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot